Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
27.66
+5.33 (23.87%)
At close: Oct 9, 2026, 4:00 PM EDT
27.90
+0.24 (0.88%)
After-hours: Oct 9, 2026, 7:38 PM EDT
Cue Biopharma Employees
Cue Biopharma had 29 employees as of December 31, 2025. The number of employees decreased by 12 or -29.27% compared to the previous year. That makes Cue Biopharma the 37,128th largest employer in the world and 5,183rd in the United States.
Employees
29
Change (1Y)
-12
Growth (1Y)
-29.27%
Revenue / Employee
$1,298,448
Profits / Employee
-$5,658,897
Market Cap
200.93M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 29 | -12 | -29.27% | 29 | 0 |
| Dec 31, 2024 | 41 | -12 | -22.64% | 41 | 0 |
| Dec 31, 2023 | 53 | 1 | 1.92% | 53 | 0 |
| Dec 31, 2022 | 52 | -7 | -11.86% | 51 | 1 |
| Dec 31, 2021 | 59 | 7 | 13.46% | 57 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Lyell Immunopharma | 161 |
| Entrada Therapeutics | 152 |
| Adagene | 128 |
| Invivyd | 122 |
| Compugen | 75 |
| Cartesian Therapeutics | 75 |
| Alpha Cognition | 71 |
| Precision BioSciences | 67 |
CUE News
- 18 days ago - B. Riley would be ‘aggressive buyers’ of Cue Biopharma after selloff - TheFly
- 18 days ago - Cue Biopharma Transcript: Study result - Transcripts
- 18 days ago - Cue Biopharma Press release: Study result - Filings
- 18 days ago - Cue Biopharma Slides: Study result - Filings
- 19 days ago - Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint - TheFly
- 19 days ago - Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria - GlobeNewsWire
- 21 days ago - Cue Biopharma initiated with a Buy at B. Riley - TheFly
- 7 weeks ago - Cue Biopharma registers to sell 1.5M shares of common stock for holders - TheFly